Jasper Posts Q2 Loss, Extends Cash Runway to 2H 2028
JSPR has more than doubled off its 52-week low of $0.315 on light trading volume (0.4× avg).
Summary
Q2 2026 results showed a $2.8M net loss and $7.3M cash, with runway guided through 2H 2028 following the $132M PIPE.
Key Events · Earnings and Guidance · JSPR
-
Q2 Net Loss of $2.8M
For the quarter ended June 30, 2026, a net loss of $2.8 million, or $0.10 per share, was recorded, compared to a $26.7 million loss in the prior year period.
-
Cash Runway Extended to 2H 2028
Management stated that the $132 million PIPE completed in July provides sufficient capital to fund planned operations through the second half of 2028.
-
Cash Position of $7.3M at Quarter End
Cash and cash equivalents totaled $7.3 million as of June 30, 2026, down from $28.7 million at December 31, 2025, reflecting pre-PIPE operating burn.
-
Clinical Milestones Set
KP-104 Phase 2 interim data are expected in Q4 2026; a pre-BLA meeting for briquilimab is expected in Q1 2027; and the KP-701 IND/CTA filing is expected in Q1 2027.
Analysis · JSPR · Life Sciences
A net loss of $2.8 million was reported for Q2, with cash of $7.3 million as of June 30, 2026. The company indicated that the $132 million PIPE completed in July provides sufficient capital to fund operations through the second half of 2028. As the first post-merger financial update, this filing offers concrete guidance on cash runway and clinical milestones—material details for a company facing going concern doubts and a Nasdaq delisting risk.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JSPR was trading at $0.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.2M. The 52-week trading range was $0.32 to $3.14. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.